Core Insights - The first China Particle Medical and Equipment Industry Development Conference was held in Chengdu, focusing on using particle technology for more precise and gentle cancer treatment [1] - Particle therapy, including proton and heavy ion therapy as well as emerging BNCT (Boron Neutron Capture Therapy), is a cutting-edge treatment method in the nuclear medical industry [1] - The particle medical industry is emerging as a trillion-yuan market, with Sichuan province, particularly Chengdu, playing a central role in developing a complete nuclear medical industry chain [1] Industry Development - Chengdu is attracting leading companies like Yuan Da Pharmaceutical and Newray, forming a collaborative industrial hub in Tianfu International Biocity, which focuses on targeted drugs, high-end equipment, and core software [2] - The future development of nuclear medicine in Chengdu will focus on three main directions: enhancing research and clinical translation of new targeted therapies and high-end diagnostic equipment, attracting corporate headquarters and R&D platforms, and providing one-stop services through policy support and platform construction [2]

Company Overview - IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology and the leading supplier of proton therapy solutions for cancer treatment [6] - IBA employs approximately 2,100 people worldwide and is a certified B Corporation, meeting high standards of social and environmental performance [6] - Universitätsklinikum Heidelberg (UKHD) is a leading modern medical center in Europe, dedicated to high-quality patient care and advanced precision medicine, particularly in radiation oncology [7] Contract Details - IBA and UKHD signed a contract for the installation of a ProteusONE compact proton therapy solution at the University campus in Heidelberg, Germany [1] - The contract includes the supply of the ProteusONE system and multi-year operation and maintenance agreements, with the first payment already received [1][3] - UKHD expects to start treating its first patients with the new system in the second half of 2030 [3] Strategic Importance - The acquisition of the ProteusONE system represents a strategic expansion of UKHD's particle therapy program, enhancing access to advanced proton therapy for cancer patients [2] - This investment strengthens UKHD's role as a global reference center for precision radiation oncology, combining scientific excellence with patient-centered innovation [2] - The typical end-user price for a ProteusONE system with a multi-year maintenance contract ranges between EUR 35 and 45 million [4] Leadership Comments - Olivier Legrain, CEO of IBA, expressed pride in collaborating with UKHD, highlighting the differentiation of IBA in the particle therapy field [4] - Prof. Dr. Jürgen Debus, Chairman of the Board at UKHD, noted that integrating IBA's equipment will help UKHD stay updated with the latest proton therapy technologies and increase patient treatment capacity [4]